TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25270701

Group type: EXPERIMENTAL
Intervention: Medical laboratory screenings (serum, urine, complete blood cell counts, standard blood chemistry panels, urinalysis)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Abnormal laboratory test results associated with kidney disease
Number of subjects: 171
Study: 22260918

Group type: EXPERIMENTAL
Intervention: Orthognathic surgery (OGS)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (orthodontic treatment only)
Number of subjects: 49
Study: 20818855

Group type: EXPERIMENTAL
Intervention: Four cycles of ABVD followed by 30 Gy of radiation therapy (group 1)
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Four cycles of ABVD followed by 20 Gy of radiation therapy (group 2)
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Two cycles of ABVD followed by 30 Gy of radiation therapy (group 3)
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Two cycles of ABVD followed by 20 Gy of radiation therapy (group 4)
Number of subjects: 1370

Group type: EXPERIMENTAL
Intervention: Four cycles of ABVD and 30 Gy of radiation therapy (group 1)
Number of subjects: 1370
Study: 18295445

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (Cardio)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Flexibility/balance (Flex)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cardio
Number of subjects: 50

Group type: COMPARATOR
Intervention: Flex
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Cardio and Flex
Number of subjects: 50
Study: 16155169

Group type: EXPERIMENTAL
Intervention: Percutaneous ethanol injection without aspiration (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Percutaneous ethanol injection with aspiration (group B)
Number of subjects: 60
Study: 14621286

Group type: EXPERIMENTAL
Intervention: Oral sodium phosphate solution (SP)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Bisacodyl combined with repeated water enemas (BE)
Number of subjects: 201
Study: 10827332

Group type: EXPERIMENTAL
Intervention: Norplant(R) contraceptive implants
Number of subjects: 1210
Study: 8675159

Group type: EXPERIMENTAL
Intervention: Venovenous bypass (VVBP)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No venovenous bypass (Control group)
Number of subjects: 77
Study: 1888824

Group type: EXPERIMENTAL
Intervention: Lansoprazole 7.5 mg
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 314

Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 314
Study: 457901

Group type: EXPERIMENTAL
Intervention: Psychodramatic Double method
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Reflection method
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Lecture method
Number of subjects: 64

Group type: COMPARATOR
Intervention: No-training control
Number of subjects: 64
Study: 30525935

Group type: EXPERIMENTAL
Intervention: Unified protocol for transdiagnostic treatment of emotional disorders
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Single-disorder protocol targeting principal diagnosis
Number of subjects: 223

Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 223
Study: 30793857

Group type: COMPARATOR
Intervention: Ostomy management reinforcement education (OMRE) - Control group (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ostomy management reinforcement education (OMRE) - Experimental group 1 (n = 20)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ostomy management reinforcement education (OMRE) - Experimental group 2 (n = 20)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ostomy management reinforcement education (OMRE) - Control vs Experimental groups
Number of subjects: 60
Study: 27890020

Group type: EXPERIMENTAL
Intervention: Choice architecture intervention (improving visibility and quality of fresh produce)
Number of subjects: 575

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 575

Group type: EXPERIMENTAL
Intervention: Choice architecture intervention
Number of subjects: 575

Group type: COMPARATOR
Intervention: Control
Number of subjects: 575
Study: 25963064

Group type: EXPERIMENTAL
Intervention: Beta Blocker Therapy
Number of subjects: 877
Study: 23748485

Group type: EXPERIMENTAL
Intervention: Palonosetron 0.25 mg IV (PAD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ondansetron 24 mg orally (OAD)
Number of subjects: 40
Study: 21135869

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily for 12 weeks
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Silodosin (RE+ patients)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 466
Study: 19590333

Group type: EXPERIMENTAL
Intervention: Application of International Classification of Injury Severity Score (ICISS) for individual patient risk stratification.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Logistic regression predictive model for mortality using ICISS survival probability (Ps).
Number of subjects: 30
Study: 17846455

Group type: EXPERIMENTAL
Intervention: Face-to-face intervention
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Internet-mediated intervention
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Internet-only intervention
Number of subjects: 192
Study: 17256680

Group type: EXPERIMENTAL
Intervention: Dual intradermal vaccination (0.1 mL at two sites)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional subcutaneous vaccination method
Number of subjects: 0
Study: 12598499

Group type: EXPERIMENTAL
Intervention: Intravenous mixed micellar K(1) 1 mg
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral mixed micellar K(1) 2 mg
Number of subjects: 44

Group type: COMPARATOR
Intervention: Oral mixed micellar K(1) 2 mg (compared to healthy infants)
Number of subjects: 44
Study: 10080041

Group type: EXPERIMENTAL
Intervention: Nicodermal patch
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Nicodermal patch with psychosocial treatment
Number of subjects: 101
Study: 8774986

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Famotidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rebamipide
Number of subjects: 0
Study: 1971117

Group type: EXPERIMENTAL
Intervention: Alpidem
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 43554

Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5 mg lorazepam
Number of subjects: 0
Study: 31740426

Group type: EXPERIMENTAL
Intervention: Intravenous N-acetylcysteine (NAC) followed by oral ramipril for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29908297

Group type: EXPERIMENTAL
Intervention: 4 mg intravenous zoledronic acid (ZOL) every 3 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 27639211

Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Medium-fidelity simulation
Number of subjects: 85
Study: 24084497

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept
Number of subjects: 177

Group type: COMPARATOR
Intervention: Sham injections
Number of subjects: 177
Study: 21950312

Group type: EXPERIMENTAL
Intervention: Spironolactone 25mg daily for 4 weeks followed by randomization to treatment or placebo for 36 weeks
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 20684019

Group type: EXPERIMENTAL
Intervention: KIDNET (narrative exposure therapy)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Waiting list (control)
Number of subjects: 26
Study: 18277346

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg daily for 5 days after abortion (Group A)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg daily for 3 days after abortion (Group B)
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg daily one day before and 2 days after abortion (Group C)
Number of subjects: 466
Study: 15637459

Group type: EXPERIMENTAL
Intervention: Amlodipine (2.5-10 mg/day)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Candesartan (2-8 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Candesartan
Number of subjects: 49
Study: 11954884

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg orally three times a day
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10526739

Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 94
Study: 7670452

Group type: EXPERIMENTAL
Intervention: Carbohydrate drink containing 1 g.kg‐1 of carbohydrate four times daily
Number of subjects: 14

Group type: COMPARATOR
Intervention: Flavored placebo
Number of subjects: 14
Study: 2404876

Group type: EXPERIMENTAL
Intervention: Immunocytochemical test using monoclonal antibodies to breast-tumor-associated antigens (BTAA)
Number of subjects: 846

Group type: EXPERIMENTAL
Intervention: Immunocytochemical diagnosis
Number of subjects: 846
Study: 6770731

Group type: EXPERIMENTAL
Intervention: Methylprednisolone, 0.5 mg/kg of body weight, intravenously every 6 h for 72 h
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo, intravenously every 6 h for 72 h
Number of subjects: 44
Study: 30606083

Group type: EXPERIMENTAL
Intervention: Non-native listeners (Dutch, Finnish, French)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Native listeners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High proficiency in non-native language
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local cues (English and Dutch)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distributed cues (Finnish and French)
Number of subjects: 0
Study: 30630622

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training and whole‐body vibration training (20Hz/2mm for first two sessions, 40Hz/4mm for the rest)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Pelvic floor muscle training alone
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training and whole‐body vibration training
Number of subjects: 61
Study: 27907978

Group type: EXPERIMENTAL
Intervention: DMAU in castor oil (100, 200, 400 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DMAU in SEDDS (100, 200, 400 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DMAU powder formulation (100, 200, 400 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DMAU (200 mg, 400 mg) with food
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: DMAU SEDDS (200 mg, 400 mg) fasting
Number of subjects: 10
Study: 23595609

Group type: EXPERIMENTAL
Intervention: 5-week cookery skills course with written educational materials
Number of subjects: 116

Group type: COMPARATOR
Intervention: Written materials only
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Cookery skills intervention
Number of subjects: 116

Group type: COMPARATOR
Intervention: Written information alone
Number of subjects: 116
Study: 24021804

Group type: EXPERIMENTAL
Intervention: Dual-mode tDCS (anodal over right PPC and cathodal over left PPC)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Single-mode tDCS (anodal over right PPC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham mode tDCS
Number of subjects: 10
Study: 21890618

Group type: EXPERIMENTAL
Intervention: Vasculitic neuropathy at baseline
Number of subjects: 506

Group type: COMPARATOR
Intervention: Microscopic polyangiitis (MPA)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Granulomatosis with polyangiitis (Wegener's)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Pure sensory neuropathy
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Patients with vasculitic neuropathy
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Chronic neuropathy
Number of subjects: 506
Study: 18457886

Group type: EXPERIMENTAL
Intervention: valsartan 160mg/amlodipine 5mg
Number of subjects: 94

Group type: COMPARATOR
Intervention: irbesartan 300mg/HCTZ 12.5mg
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: valsartan 160mg/amlodipine
Number of subjects: 94
Study: 17671918

Group type: EXPERIMENTAL
Intervention: Day care treatment
Number of subjects: 191

Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 191
Study: 15193686

Group type: EXPERIMENTAL
Intervention: Fasting glucose levels (measured in mg/dl)
Number of subjects: 829
Study: 10705179

Group type: EXPERIMENTAL
Intervention: Carbachol stimulation in acalculous biliary pain group
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CCK stimulation in acalculous biliary pain group
Number of subjects: 11

Group type: COMPARATOR
Intervention: CCK stimulation in gallstone patients
Number of subjects: 11

Group type: COMPARATOR
Intervention: CCK stimulation in normal controls
Number of subjects: 11
Study: 9321729

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanic acid
Number of subjects: 440

Group type: COMPARATOR
Intervention: Clindamycin + Gentamicin
Number of subjects: 440
Study: 8458189

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg tds for 24 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study: 3825160

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: K-strophanthine
Number of subjects: 0
Study: 31048414

Group type: EXPERIMENTAL
Intervention: Corticosteroids and IVIg
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Infliximab and IVIg
Number of subjects: 121

Group type: COMPARATOR
Intervention: IVIg only
Number of subjects: 121
Study: 29773539

Group type: EXPERIMENTAL
Intervention: Tailored text message based diabetes self management support (SMS4BG) for up to nine months in addition to usual care.
Number of subjects: 366

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 366
Study: 27816090

Group type: EXPERIMENTAL
Intervention: Randomized controlled studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intent-to-treat statistical methods
Number of subjects: 0
Study: 24793816

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine (3.6 mg/kg intravenously every 21 days)
Number of subjects: 602

Group type: COMPARATOR
Intervention: Physician's choice
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Number of subjects: 602
Study: 22273498

Group type: EXPERIMENTAL
Intervention: 800-nm diode laser treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Untreated contralateral side
Number of subjects: 21

Group type: COMPARATOR
Intervention: Comparison between treated and untreated sides
Number of subjects: 21
Study: 19664010

Group type: EXPERIMENTAL
Intervention: Oral midazolam
Number of subjects: 61

Group type: COMPARATOR
Intervention: i.v. midazolam
Number of subjects: 61
Study: 18568379

Group type: EXPERIMENTAL
Intervention: ASPIRE group (n = 20)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard educationally-based treatment group (n = 20)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Wait list control group (n = 19)
Number of subjects: 59
Study: 16473225

Group type: EXPERIMENTAL
Intervention: AcrySof Natural intraocular lens (IOL)
Number of subjects: 30

Group type: COMPARATOR
Intervention: AcrySof SA60AT intraocular lens (control group)
Number of subjects: 30
Study: 12429360

Group type: EXPERIMENTAL
Intervention: Paroxetine 40 mg/day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paroxetine 20 mg/day plus amisulpride 50 mg/day
Number of subjects: 60
Study: 10889816

Group type: EXPERIMENTAL
Intervention: IDEIA PCE chlamydia
Number of subjects: 380

Group type: COMPARATOR
Intervention: Amplicor PCR
Number of subjects: 380

Group type: COMPARATOR
Intervention: PCR and IDEIA PCE
Number of subjects: 380
Study: 8638831

Group type: EXPERIMENTAL
Intervention: Nitrous oxide at concentrations of 0, 20, 40, 60, and 75 vol%
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 25
Study: 1460750

Group type: EXPERIMENTAL
Intervention: Enflurane (1.49 MAC hours)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Isoflurane (2.17 MAC hours)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Sevoflurane (1.29 MAC hours)
Number of subjects: 27
Study: 6330716

Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 31067358

Group type: EXPERIMENTAL
Intervention: High-dose interferon-α (HDI)
Number of subjects: 2000
Study: 29110140

Group type: EXPERIMENTAL
Intervention: IDgenetix®
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IDgenetix® in patients with severe depression
Number of subjects: 0
Study: 26689590

Group type: EXPERIMENTAL
Intervention: Digital home ovulation tests (OTs)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Advice to have intercourse every 2-3 days
Number of subjects: 36
Study: 23763990

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with unspecific attention control
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with specific electrical attention control
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS) with visual attention focus
Number of subjects: 10
Study: 22196464

Group type: EXPERIMENTAL
Intervention: Prophylactic transfusion of FFP omitted
Number of subjects: 0

Group type: COMPARATOR
Intervention: Transfusion of a fixed dose of 12 ml/kg of FFP
Number of subjects: 0
Study: 19595251

Group type: EXPERIMENTAL
Intervention: Thymosin alpha(1) Group (n = 23)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CBP Group (n = 22)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Combined Therapy Group (n = 22)
Number of subjects: 91

Group type: COMPARATOR
Intervention: CBP Group, Combined Therapy Group, Thymosin alpha(1) Group
Number of subjects: 91
Study: 16817289

Group type: EXPERIMENTAL
Intervention: Trillium-coated oxygenator (TC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-coated oxygenator (NC)
Number of subjects: 20
Study: 14508796

Group type: EXPERIMENTAL
Intervention: Methacholine
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Flow-mediated dilation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Nitroglycerin-induced dilation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Antioxidant vitamin C
Number of subjects: 36

Group type: COMPARATOR
Intervention: L-arginine
Number of subjects: 36
Study: 11382368

Group type: EXPERIMENTAL
Intervention: Supervised group (directly observed isoniazid therapy twice weekly)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Peer group (daily self‐administered isoniazid with peer counseling and education)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine group (routine care)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Immediate incentives
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Deferred incentives
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Supervised group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Peer group
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine group
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Peer group (n = 27)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine group (n = 32)
Number of subjects: 300
Study: 9233181

Group type: EXPERIMENTAL
Intervention: Event Monitor (EM)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Daily log
Number of subjects: 11

Group type: COMPARATOR
Intervention: Recall method
Number of subjects: 11
Study: 7952457

Group type: EXPERIMENTAL
Intervention: Suction group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Water-seal group
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 3302918

Group type: EXPERIMENTAL
Intervention: Erythromycin-sulfisoxazole (E/S)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Erythromycin-sulfisoxazole (E/S) and Cefaclor
Number of subjects: 119
Study: 2781241

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic method for estimating hepatic plasma flow and extraction ratio of indocyanine green
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fick principle method for estimating hepatic plasma flow and extraction ratio of indocyanine green
Number of subjects: 0
Study: 31508999

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation plus oral antibiotic bowel preparation (neomycin and metronidazole)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Mechanical bowel preparation
Number of subjects: 311
Study: 30977385

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks with chemotherapy (capecitabine or gemcitabine/carboplatin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo every 3 weeks with chemotherapy (capecitabine or gemcitabine/carboplatin)
Number of subjects: 0
Study: 29806315

Group type: EXPERIMENTAL
Intervention: Arthroscopic separate double-layer suture bridge technique (trial group)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Arthroscopic whole-layer suture bridge technique (control group)
Number of subjects: 54
Study: 26378949

Group type: COMPARATOR
Intervention: Fitkids Treadmill Test (FTT)
Number of subjects: 68
Study: 23385793

Group type: EXPERIMENTAL
Intervention: Altered spherical aberration and vision training
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Altered spherical aberration only
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Vision training only
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control
Number of subjects: 177
Study: 21648012

Group type: EXPERIMENTAL
Intervention: Phytosterol/stanol-enriched functional foods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmaceutical care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phytosterol/stanol users in usual care group
Number of subjects: 0
Study: 18327433

Group type: EXPERIMENTAL
Intervention: MPH-SODAS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16